Clinical Trial Update: Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating perifosine in patients with refractory solid tumors and hematologic cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• Perifosine (perifosine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED